HLS Therapeutics Inc.
HLS Therapeutics Inc. (HLS.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hls.to · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Hold
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $4.40
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.32 | ↓ 1.87% |
1-day model range: $4.31–$4.33. Peak: $4.33 (-1.87%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $4 | -8.7% |
| 2028 | $4 | -12.7% |
| 2029 | $4 | -14.6% |
| 2030 | $4 | -15.6% |
| 2031 | — | -16.0% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HLS.TO · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-03-18 | Raymond James | Maintains | Market Perform→Market Perform |
| 2021-08-06 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
Wall Street analysts have recently issued updated ratings on HLS Therapeutics Inc. (HLS.TO) stock. Of the recent 2 rating actions, 0 were upgrades and 1 were downgrades. 1 analysts currently cover HLS.TO.
Analyst Recommendation Trends
HLS.TO analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$58M
↓ 24.8% YoY
Revenue Next Year
$64M
↑ 10.8% YoY
EPS This Year
$-0.27
EPS Next Year
$-0.03
↓ 88.9% YoY
EPS ForecastReported vs Estimated
Analysts forecast HLS.TO EPS of $-0.27 for the current fiscal year, based on estimates from 2 analysts. The HLS.TO revenue forecast is $58M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HLS.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HLS.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The HLS.TO short-term stock prediction for tomorrow is $4.32 (-1.87%). The HLS.TO stock price prediction for 2027 estimates an average of $4. The HLS.TO stock prediction for 2030 projects a range of $4–$4.
HLS Therapeutics Inc. trades on TSX under the ticker HLS.TO. The HLS.TO stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
HLS.TO forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month HLS.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $4.40.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.